Drug Profile
Bucindolol companion diagnostic - Laboratory Corporation of America Holdings
Alternative Names: Gencaro™ companion diagnosticLatest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator ARCA biopharma Inc
- Developer ARCA biopharma Inc; Laboratory Corporation of America Holdings
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Atrial fibrillation
- Discontinued Heart failure
Most Recent Events
- 27 Sep 2021 Phase-II/III development is still ongoing for Atrial fibrillation (Diagnosis) in USA, Canada, Hungary, Netherlands, Poland, Serbia (PO) (ARCA biopharma pipeline, September 2021)
- 13 Jul 2016 Phase-II/III clinical trials in Atrial fibrillation (Diagnosis) in Poland (PO) (EudraCT2016-000302-12)
- 08 Nov 2014 Discontinued - Clinical-Phase-Unknown for Heart failure (Diagnosis) in USA (unspecified route)